CS3005 / CStone Pharma - LARVOL DELTA

A Study of CS3005 in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=9 | Completed | Sponsor: CStone Pharmaceuticals | Recruiting ➔ Completed | N=24 ➔ 9

Enrollment change • Trial completion • Oncology • Solid Tumor

A Study of CS3005 in Advanced Solid Tumors (clinicaltrials.gov) - P1; N=24; Recruiting; Sponsor: CStone Pharmaceuticals

Clinical • New P1 trial

Role of the XylA gene, encoding a cell wall degrading enzyme, during common wheat, durum wheat and barley colonization by Fusarium graminearum. (PubMed, Fungal Genet Biol) - "This study investigated the role of the F. graminearum XylA (FGSG_10999) gene during infection, using a knockout mutant in strain CS3005...A positive correlation between symptom incidence and fungal biomass development was also observed for both the wild type and the knockout strains. Finally, gene expression studies performed in a liquid medium enriched with D-xylose, a known xylanase inducer in other fungi, showed that the absence of the gene in the FGSG_10999 locus was not compensated by two other F. graminearum xylanase encoding genes analysed (loci FGSG_06445 and FGSG_11478)."

Journal

CStone completes registration filing for the phase I trial of its tumor immune microenvironment modulator CS3005 to enable study initiation in Australia (PRNewswire) - "CStone Pharmaceuticals...announced that the Company has recently received the approval from the Human Research Ethics Committee (HREC) in Australia, and the acknowledgement from Australia's Therapeutic Goods Administration (TGA) on the Phase I clinical trial of CS3005. This Phase I trial is an open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of CS3005 in patients with advanced solid tumors."

Clinical